Tag:
Tysabri
Latest Headlines
Latest Headlines
Tysabri label change could add $1B to sales
Biogen Idec ( $BIIB ) has pulled off a big coup in personalized medicine. The multiple sclerosis drug Tysabri has long been weighed down by a well-known safety risk: It's linked with a potentially
Quest's companion diagnostic confronts Tysabri brain infection risk
It's a vexing problem that certain drugs with enormous benefit can also carry significant health risk. Case in point: Some patients who take the multiple sclerosis drug Tysabri experience improved
Biogen takes European MS marketing in-house with JV buyouts
Biogen Idec ( $BIIB ) is taking its multiple sclerosis marketing in-house. The Massachusetts-based company has bought out the joint-venture partner that had been selling Avonex and Tysabri, forming
FDA: Tysabri risks greatest during year 3
The FDA has updated its warning on Biogen Idec's multiple sclerosis drug Tysabri. According to the agency, the risk of a potentially fatal brain infection appears to be greatest during the third year
Amgen profits drop; Gilead HIV sales suffer
Quarterly earnings reports continue to pour in, highlighting some successful new drugs--and some older ones, too. Amgen, for instance, posted sales of its Xgeva bone drug that far outpaced analyst
Biogen expects MS sales hit from Gilenya
We've heard a lot about Novartis' new multiple sclerosis drug Gilenya, the first oral treatment for the disease. It has hit the ground running, growing sales and grabbing market share just as the
Biogen wants to put PML marker on Tysabri label
Biogen Idec ( $BIIB ) has followed through on its promise to keep the public apprised about the safety of its multiple sclerosis drug Tysabri. Monthly, the company has been updating us with new case
Biogen discloses PML cases, one death in Tysabri patients
Four more patients taking Biogen Idec's multiple sclerosis drug Tysabri have developed the serious brain infection known as progressive multifocal leukoencephalopathy (PML), and one of them died,
PML risk test could boost Biogen's Tysabri—if it works
What if Biogen Idec could identify the multiple sclerosis patients who are most likely to develop Tysabri's worst side effect? No more blind worry about progressive multifocal leukoencephalopathy, or
FDA warns Biogen, Gilead on DTC promos
Continuing its tougher stance on drug company advertising, the FDA sent out warning letters to Biogen Idec and Gilead Sciences, citing them for minimizing the risks of treatment with their drugs.
